ABL1 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

ABL1 is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain ABL1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 5 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain AFF1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

ASXL1 is altered in 1.86% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL2 is altered in 1.19% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

BCL2 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain BCL2 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

BCL6 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain BCL6 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

BCR is altered in 0.34% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

BCR is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain BCR status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

BTK is altered in 1.31% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

BTK is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BTK status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 2 are phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain CBFB status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [3].

DEK is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain DEK status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

DNMT3A is altered in 4.57% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain ELL status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

FGFR3 is altered in 0.51% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain FLT3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

IGH is altered in 3.4% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

IGH is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

IKZF1 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

IKZF1 is an inclusion eligibility criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [3].

KIT is altered in 0.51% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

KIT is an inclusion eligibility criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].

KMT2A is altered in 1.69% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 5 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain KMT2A status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MAF is altered in 0.54% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

MAF is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is altered in 0.52% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

MAFB is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is altered in 0.96% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

MECOM is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 3 are open and 3 are closed. Of the trials that contain MECOM status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLF1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain MLLT1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain MLLT10 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain MLLT3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain MLLT4 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MYC is altered in 1.36% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

MYC is an inclusion eligibility criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MYC status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYH11 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [3].

NOTCH1 is altered in 11.19% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

NOTCH1 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NOTCH1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NPM1 is an inclusion eligibility criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain NRIP3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

NUP214 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain NUP214 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

PBX1 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 2 are closed. Of the trials that contain PBX1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [3].

PHF6 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PLCG2 is altered in 1.05% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

PLCG2 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PLCG2 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 2 are phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 3 are open and 3 are closed. Of the trials that contain RPN1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

RUNX1 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [3].

RUNX1T1 is altered in 0.54% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

RUNX1T1 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1T1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [3].

TCF3 is altered in 2.34% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

TCF3 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 2 are closed. Of the trials that contain TCF3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [3].

TET2 is altered in 4.74% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 16.24% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 11 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 6 are open and 5 are closed. Of the trials that contain TP53 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [3].

WHSC1 is altered in 0.53% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [2].

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].